On Tuesday, the shares of Hong Kong drifted at a 5-month high, hoisted by the power in the Chinese property stocks following improvement in sales of homes in the mainland.
However, the profits on the index were capped by a drop in banking stocks as the investors sought out for gains from a rally previous week on reports that a unit of sovereign wealth fund China Investment Corp, Central Huijin will hike the stakes in the ‘Big Four’ banks of China.
The CSI300 of the leading Shenzen and Shanghai listings progressed 0.8% in the mainland, while Shanghai Composite Index profited 0.6%.
Hang Seng Index increased to 21,208.8, indicating an increase of 0.3% at mid-day after the peak intra day levels were briefly tested since May 2nd. The leading Chinese listings of China Enterprises Index in Hong Kong edged up 0.1%.
The volumes were largely focused on Chinese property and banking sectors even as wider turnover remained dull in both of these markets.
Haitong International Securities’ equity strategist, Edward Huang said that investors were boding with those sectors, for which they have a reason to be sure of. Such a rotation indicates that they are also placing themselves for the subsequent leg up.
China Resources Land increased 4.4%, while China Overseas Land profited 2.6% following the improvement of property transactions of the property consultancies Soufun and Centaline in the mainland. Both these stocks were stragglers in the previous week, dropping 2.2% and 3.7% respectively as against Hang Seng Index’s 0.6% profit.
China Resources Land went up 37% for the year after 2 consecutive yearly losses, but it is trading at still a forward twelve-month earnings multiple, as per Thomson Reuters StarMine.
The Chinese banks were mostly weaker. China Construction Bank (CCB) was down 0.2% in Shanghai and 1.6% in Hong Kong. CCB experienced its best week during the last week in Hong Kong, increasing 5.3%.
Ping An Insurance Inches Up
Ping An Insurance climbed 0.7% in Shanghai and 0.8% in Hong Kong after it posted a 12% growth in September’s premium income as against a year back.
It reported a 17% gain in life insurance premiums in the 3rd quarter as against a year back, up from 10% in 2nd quarter and 2% in the 1st.
The analysts from Barclays Capital said that overall those figures indicated the volume growth of Ping An could be turning constructive, which is expected to enhance its outlook of New Business Value (NBV).
Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)
Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.
Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.
Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).
That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).
The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.
Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.
The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.
Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.
Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)
Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.
Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.
Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.
Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.
The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.
Bristol-Myers declined to comment.
Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.
The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.
Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.
On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.
Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.
The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.